- TriSalus Life Sciences (TLSI, Financial) is initiating a pivotal exchange offer for its Series A Convertible Preferred Stock.
- Analysts foresee a significant upside potential with a 113.85% increase from the current stock price.
- The company's recommendation status from brokerage firms is an encouraging "Outperform."
TriSalus Life Sciences (TLSI) has commenced a strategic initiative to convert its Series A Convertible Preferred Stock into common stock at a conversion rate of $4 per share. This exchange offer, which will conclude on July 23, 2025, aims to simplify the company's capital structure and bolster equity transparency by targeting up to 11,860,206 shares.
Wall Street Analysts' Forecast
Delving into analysts' predictions, a consensus of eight financial experts provides a one-year price target for TriSalus Life Sciences Inc (TLSI, Financial), with an average estimate set at $11.31. The projections vary, with a high forecast of $16.00 and a low forecast of $9.00. This average target projects an impressive upside of 113.85% from the prevailing price of $5.29. For more comprehensive estimate data, visit the TriSalus Life Sciences Inc (TLSI) Forecast page.
Brokerage Firm Recommendations
The collective assessment from eight brokerage firms results in an average recommendation for TriSalus Life Sciences Inc (TLSI, Financial) currently positioned at 1.9 on the rating scale, which indicates an "Outperform" status. This scale is calibrated from 1 to 5, where 1 denotes a Strong Buy, and 5 signals a Sell.
